Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma
Salim Kanoun, Ṭal Ilan, Alina Berriolo-Riedinger, et al.
PLoS ONE (2015) Vol. 10, Iss. 10, pp. e0140830-e0140830
Open Access | Times Cited: 101

Showing 1-25 of 101 citing articles:

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies
Michel Meignan, Anne‐Ségolène Cottereau, Annibale Versari, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 30, pp. 3618-3626
Closed Access | Times Cited: 278
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
Anne‐Ségolène Cottereau, Annibale Versari, Annika Loft, et al.
Blood (2018) Vol. 131, Iss. 13, pp. 1456-1463
Open Access | Times Cited: 163
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Justin Jee, Emily S. Lebow, Randy Yeh, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2353-2363
Open Access | Times Cited: 111
Response-adapted anti-PD-1–based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE
Matthew Mei, Hun Ju Lee, Joycelynne Palmer, et al.
Blood (2022) Vol. 139, Iss. 25, pp. 3605-3616
Open Access | Times Cited: 87
Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma
Hajira Ilyas, N. George Mikhaeel, Joel Dunn, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2018) Vol. 45, Iss. 7, pp. 1142-1154
Open Access | Times Cited: 126
Deep-Learning 18F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma
Nicolò Capobianco, Michel Meignan, Anne‐Ségolène Cottereau, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 1, pp. 30-36
Open Access | Times Cited: 102
qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT
Andrei Gafita, Marie Bieth, Martin Krönke, et al.
Journal of Nuclear Medicine (2019) Vol. 60, Iss. 9, pp. 1277-1283
Open Access | Times Cited: 100
Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: A meta-analysis
Baoping Guo, Xiaohong Tan, Qing Ke, et al.
PLoS ONE (2019) Vol. 14, Iss. 1, pp. e0210224-e0210224
Open Access | Times Cited: 98
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation
Mani Akhtari, Sarah A. Milgrom, Chelsea C. Pinnix, et al.
Blood (2017) Vol. 131, Iss. 1, pp. 84-94
Open Access | Times Cited: 92
Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR)
Nandita M. deSouza, Eric Achten, Ángel Alberich‐Bayarri, et al.
Insights into Imaging (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 80
Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium
Sally F. Barrington, Gerben J. C. Zwezerijnen, Henrica C. W. de Vet, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 3, pp. 332-337
Open Access | Times Cited: 79
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
David Chardin, M. Paquet, Renaud Schiappa, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 2, pp. e000645-e000645
Open Access | Times Cited: 72
Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review
Russell Frood, Christopher Burton, Charalampos Tsoumpas, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 10, pp. 3198-3220
Open Access | Times Cited: 65
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial
Luc‐Matthieu Fornecker, Julien Lazarovici, Igor Aurer, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 2, pp. 327-335
Open Access | Times Cited: 43
International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation
Ronald Boellaard, Irène Buvat, Christophe Nioche, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 9, pp. 1343-1348
Closed Access | Times Cited: 11
Results From First-in-Human Phase I Study of a Novel CD19-1XX Chimeric Antigen Receptor With Calibrated Signaling in Large B-Cell Lymphoma
Jae H. Park, M. Lia Palomba, Karlo Perica, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
Mira Tout, Olivier Casasnovas, Michel Meignan, et al.
Blood (2017) Vol. 129, Iss. 19, pp. 2616-2623
Open Access | Times Cited: 80
Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma
Jasmin Mettler, Horst Müller, Conrad‐Amadeus Voltin, et al.
Journal of Nuclear Medicine (2018) Vol. 60, Iss. 2, pp. 207-211
Open Access | Times Cited: 73
Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma
Marius E. Mayerhoefer, Christopher C. Riedl, Anita Kumar, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2019) Vol. 46, Iss. 13, pp. 2760-2769
Open Access | Times Cited: 68
The role of PET/CT in the modern treatment of Hodgkin lymphoma
Jan Maciej Zaucha, Stéphane Chauvie, Renata Zaucha, et al.
Cancer Treatment Reviews (2019) Vol. 77, pp. 44-56
Closed Access | Times Cited: 66
The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
Julia Driessen, Gerben J. C. Zwezerijnen, Heiko Schöder, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 9, pp. 1424-1430
Open Access | Times Cited: 38
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial
Anne‐Ségolène Cottereau, Louis Rebaud, Judith Trotman, et al.
Annals of Oncology (2023) Vol. 35, Iss. 1, pp. 130-137
Open Access | Times Cited: 17
DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
Justin Jee, A. Rose Brannon, Rohan Kumar Singh, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2499-2507
Open Access | Times Cited: 6
Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma
Anne‐Ségolène Cottereau, Sébastien Hapdey, Loïc Chartier, et al.
Journal of Nuclear Medicine (2016) Vol. 58, Iss. 2, pp. 276-281
Open Access | Times Cited: 57
Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma
Mingge Zhou, Yumei Chen, Honghui Huang, et al.
Oncotarget (2016) Vol. 7, Iss. 50, pp. 83544-83553
Open Access | Times Cited: 57
Page 1 - Next Page

Scroll to top